Vorasidenib Expanded Access Program

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma

NCT01378481 ·Status: TERMINATED ·Phase: PHASE1

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

NCT07286292 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT05588141 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma

NCT03893903 ·Status: COMPLETED ·Phase: PHASE1

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

NCT02481154 ·Status: COMPLETED ·Phase: PHASE1

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

NCT05609994 ·Status: RECRUITING ·Phase: PHASE1

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

NCT01434602 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

NCT04590664 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519 ·Status: RECRUITING ·Phase: PHASE3

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

NCT05076513 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

NCT02977689 ·Status: WITHDRAWN ·Phase: PHASE2

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

NCT02704858 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

NCT05859334 ·Status: RECRUITING ·Phase: PHASE2

G207 Followed by Radiation Therapy in Malignant Glioma

NCT00157703 ·Status: COMPLETED ·Phase: PHASE1

Sorafenib in Newly Diagnosed High Grade Glioma

NCT00884416 ·Status: COMPLETED ·Phase: PHASE1

Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00238303 ·Status: COMPLETED ·Phase: PHASE2

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641 ·Status: RECRUITING ·Phase: PHASE1

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

NCT03343197 ·Status: COMPLETED ·Phase: PHASE1

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

NCT03718767 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

NCT01547546 ·Status: COMPLETED ·Phase: PHASE1

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

NCT01257594 ·Status: COMPLETED ·Phase: PHASE1

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751 ·Status: COMPLETED ·Phase: PHASE2

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

NCT04712721 ·Status: TERMINATED ·Phase: EARLY_PHASE1

AMG 595 First-in-Human in Recurrent Gliomas

NCT01475006 ·Status: COMPLETED ·Phase: PHASE1